Yes, cilostazol can and should be added to aspirin in this patient with severe PAD (ABI 0.4) and claudication while awaiting vascular specialist evaluation.
Rationale for Adding Cilostazol
Cilostazol (100 mg twice daily) is a Class I recommendation (Level of Evidence A) for patients with PAD and intermittent claudication 1, 2. This patient meets clear criteria for cilostazol therapy:
- Symptomatic claudication requiring treatment
- Severe PAD (ABI 0.4 indicates significant arterial obstruction)
- Already on aspirin for cardiovascular protection
- Awaiting specialist evaluation - cilostazol provides symptomatic benefit during this interval
Key Clinical Considerations
Safety of Combination Therapy
The combination of cilostazol with aspirin is safe and does not increase bleeding risk 3. A crossover trial in 21 PAD patients demonstrated that:
- Aspirin alone increased bleeding time
- Cilostazol alone did NOT increase bleeding time
- Adding cilostazol to aspirin caused no further bleeding time prolongation
The 2012 ACCP guidelines specifically recommend adding cilostazol (100 mg bid) to aspirin (75-100 mg/d) for patients with refractory claudication (Grade 2C) 4.
Expected Benefits
Cilostazol provides:
- 40-60% improvement in maximal walking distance after 12-24 weeks 5, 6
- Symptom improvement visible as early as 2-4 weeks 6
- Improved quality of life and functional status 2
- Potential reduction in restenosis if endovascular intervention is later performed 2
Critical Contraindication to Screen For
Do NOT prescribe cilostazol if the patient has heart failure of ANY severity 1, 2, 6. This is an FDA black-box warning due to concerns about phosphodiesterase III inhibitor class effects on mortality in heart failure patients 5.
Practical Implementation
Dosing
Common Side Effects to Counsel About
- Headache (most common)
- Diarrhea
- Dizziness
- Palpitations
- Approximately 20% discontinue within 3 months due to side effects 2
Follow-up Strategy
- Assess tolerance at 2-4 weeks to determine if patient can continue therapy 2
- Evaluate benefit at 3-6 months to decide on long-term continuation 2
- If gastrointestinal intolerance to aspirin develops, consider switching to clopidogrel 75 mg daily 7
Additional Management While Awaiting Specialist
Beyond cilostazol, ensure this patient receives:
- High-intensity statin therapy (LDL-C goal <55 mg/dL) 2, 8
- Supervised exercise therapy (30-45 minutes, 3x/week minimum) - Class I recommendation 1
- Aggressive cardiovascular risk factor modification (blood pressure, diabetes control, smoking cessation)
Why This Matters for This Specific Patient
With an ABI of 0.4, this patient has severe PAD placing them at high risk for:
- Major adverse cardiovascular events
- Limb complications
- Progression to critical limb-threatening ischemia
Starting cilostazol immediately provides symptomatic relief and may improve outcomes if revascularization is ultimately performed 2, 9. The delay until vascular specialist evaluation should not prevent initiation of guideline-directed medical therapy that can begin improving symptoms within weeks.